The Delhi High Court has granted permission to Zydus to market a more affordable biosimilar version of the cancer medication Nivolumab, citing public interest.
The Delhi High Court has given a significant ruling in favor of Zydus, a pharmaceutical company, allowing it to sell a biosimilar version of the cancer drug Nivolumab at a lower price. Nivolumab, marketed under the brand name Opdivo by Bristol Myers Squibb, is a...
Piramal Pharma Enhances Its Global Sustainability Rating in Recent Corporate Assessment.
Piramal Pharma, a leading global pharmaceutical company, has achieved a significant improvement in its score on the Global Corporate Sustainability Assessment (CSA) conducted by S&P Global. The CSA is a widely recognized benchmark for assessing a company's...
Aurobindo Pharma Acquires Khandelwal Labs’ Non-Cancer Portfolio for ₹325 Crore.
Aurobindo Pharma, a leading Indian pharmaceutical company, has acquired the non-oncology business of Khandelwal Laboratories for ₹325 crore. The acquisition is a strategic move by Aurobindo Pharma to expand its product portfolio and strengthen its position in the...
Lupin partners with Gan & Lee to bring fortnightly GLP-1 treatment to India through exclusive licensing deal.
Lupin Limited, a global pharmaceutical company, has entered into an exclusive agreement with Gan&Lee Pharmaceuticals of China to commercialize Bofanglutide, a novel GLP-1 receptor agonist, in India. Bofanglutide is a fortnightly treatment for type 2 diabetes and...
Delhi High Court grants permission to Zydus to market Nivolumab biosimilar, a cancer treatment drug, in India.
The Delhi High Court has allowed Zydus Lifesciences to sell and market its biosimilar version of the anti-cancer drug nivolumab in India, despite a patent infringement suit filed by the innovator and patent holder, E.R. Squibb & Sons LLC. The court modified a previous...
Alkem’s Renocia kit offers a cyclical nutritional supplement therapy designed to promote healthy hair growth.
Alkem Laboratories has launched a new product called Renocia cyclical therapy kit, a weekly nutritional supplementation regimen designed to support hair growth, strengthen hair follicles, and manage hair loss. The kit contains a set of vegetarian-sourced supplements,...
Mylan and Aurobindo Pharma must defend against allegations of colluding to fix prices for generic drugs.
A federal judge in Connecticut has rejected a request by Mylan Pharmaceuticals and Aurobindo Pharma USA to dismiss antitrust litigation against them. The judge ruled that a coalition of states has presented sufficient evidence to raise a genuine dispute about whether...
Biocon Biologics enhances its cancer treatment offerings with the introduction of three key biosimilar products.
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Limited, has announced plans to expand its oncology portfolio with the introduction of three new biosimilar candidates. The new additions include biosimilar versions of Trastuzumab/Hyaluronidase, Nivolumab, and...
Sun Pharmaceutical Industries has secured approval from the US Food and Drug Administration for an updated label of UNLOXCYT, incorporating long-term efficacy data for Cutaneous Squamous Cell Carcinoma treatment.
Sun Pharmaceutical Industries Ltd. has received approval from the US Food and Drug Administration (USFDA) for an updated label for its medication UNLOXCYT (tretinoin), which is used to treat a rare skin condition called Cutaneous Squamous Cell Carcinoma (CSCC) in...
Sun Pharma Secures Rs 828 Crore Refund as CESTAT Declares Revenue Department’s Demand as Legally Invalid
Sun Pharmaceutical Industries, one of India's largest pharmaceutical companies, has won a significant excise refund battle. The Customs, Excise, and Service Tax Appellate Tribunal (CESTAT) ruled in favor of Sun Pharma, dismissing a revenue demand of Rs 828 crore...
Sun Pharma’s US revenue from innovative medicines now exceeds that of its generic offerings.
Sun Pharmaceutical Industries Ltd. has reported a significant shift in its business mix, with innovative medicines outpacing generic drug sales in the United States during the second quarter of fiscal year 2026. The company's innovative medicines, including Ilumya,...
Sun Pharma’s Q2 net profit has increased by 2.5% to ₹3,118 crore, with a 9% year-over-year revenue growth, despite a 4.1% decline in US sales.
Sun Pharmaceutical Industries has announced its Q2 results, showing a 2.5% increase in net profit to ₹3,118 crore. The company's revenue growth stood at 9% year-over-year (YoY), driven by strong performance in the domestic market and emerging markets. However, US...
Next week, several major companies, including Airtel, LIC, SBI, M&M, Sun Pharma, and Titan, are set to release their Q2 earnings reports.
The Indian corporate sector has reported earnings in line with expectations for the September quarter, boosting market sentiment. Several prominent companies, including Indian Oil Corporation, Adani Green Energy, and Hindustan Petroleum Corporation Limited, have...
The US Food and Drug Administration (USFDA) has conducted an inspection of Unit 1 at Divi’s Laboratories Limited.
The US Food and Drug Administration (USFDA) recently conducted an inspection of Unit 1 of Divi's Laboratories Limited, a leading pharmaceutical company based in India. The inspection was a routine evaluation of the company's compliance with current Good Manufacturing...
Natco Pharma’s Q2 net profit plunges 23.44% to Rs 517.9 crore
Natco Pharma, a leading Indian pharmaceutical company, has reported a decline in its net profit for the second quarter (Q2) of the current financial year. The company's net profit stood at Rs 517.9 crore, which represents a decline of 23.44% compared to the same...
Indian pharmaceutical companies Cipla, Natco, Hetero, and Annora have secured major contracts to supply generic drugs to the Chinese market.
Cipla, Natco, Hetero, and Annora, four prominent Indian pharmaceutical companies, have secured significant contracts to supply generic drugs to China. This development marks a major breakthrough for Indian pharmaceutical companies in the Chinese market. The contracts...
Delhi High Court’s Decision in F. Hoffmann-La Roche Ag & Anr. v. Natco Pharma – Cyril Amarchand Mangaldas
The Delhi High Court recently delivered a significant judgment in the case of F. Hoffmann-La Roche Ag & Anr. vs. Natco Pharma, which has far-reaching implications for the pharmaceutical industry. The court's ruling pertains to the interpretation of Section 107A of the...
NATCO Pharma Limited’s ability to maintain steady cash flow during economic downturns is being reassessed.
NATCO Pharma Limited is an Indian pharmaceutical company that has been facing challenges in maintaining stable cash flow during market downturns. According to recent statistics, the company's cash flow has been volatile, with significant fluctuations in its operating...
The Delhi High Court has granted permission to Zydus to market a more affordable biosimilar version of the cancer medication Nivolumab, citing public interest.
The Delhi High Court has given a significant ruling in favor of Zydus, a pharmaceutical company, allowing it to sell a biosimilar version of the cancer drug Nivolumab at a lower price. Nivolumab, marketed under the brand name Opdivo by Bristol Myers Squibb, is a...
Piramal Pharma Enhances Its Global Sustainability Rating in Recent Corporate Assessment.
Piramal Pharma, a leading global pharmaceutical company, has achieved a significant improvement in its score on the Global Corporate Sustainability Assessment (CSA) conducted by S&P Global. The CSA is a widely recognized benchmark for assessing a company's...
Aurobindo Pharma Acquires Khandelwal Labs’ Non-Cancer Portfolio for ₹325 Crore.
Aurobindo Pharma, a leading Indian pharmaceutical company, has acquired the non-oncology business of Khandelwal Laboratories for ₹325 crore. The acquisition is a strategic move by Aurobindo Pharma to expand its product portfolio and strengthen its position in the...
Lupin partners with Gan & Lee to bring fortnightly GLP-1 treatment to India through exclusive licensing deal.
Lupin Limited, a global pharmaceutical company, has entered into an exclusive agreement with Gan&Lee Pharmaceuticals of China to commercialize Bofanglutide, a novel GLP-1 receptor agonist, in India. Bofanglutide is a fortnightly treatment for type 2 diabetes and...
Delhi High Court grants permission to Zydus to market Nivolumab biosimilar, a cancer treatment drug, in India.
The Delhi High Court has allowed Zydus Lifesciences to sell and market its biosimilar version of the anti-cancer drug nivolumab in India, despite a patent infringement suit filed by the innovator and patent holder, E.R. Squibb & Sons LLC. The court modified a previous...
Alkem’s Renocia kit offers a cyclical nutritional supplement therapy designed to promote healthy hair growth.
Alkem Laboratories has launched a new product called Renocia cyclical therapy kit, a weekly nutritional supplementation regimen designed to support hair growth, strengthen hair follicles, and manage hair loss. The kit contains a set of vegetarian-sourced supplements,...
Mylan and Aurobindo Pharma must defend against allegations of colluding to fix prices for generic drugs.
A federal judge in Connecticut has rejected a request by Mylan Pharmaceuticals and Aurobindo Pharma USA to dismiss antitrust litigation against them. The judge ruled that a coalition of states has presented sufficient evidence to raise a genuine dispute about whether...
Biocon Biologics enhances its cancer treatment offerings with the introduction of three key biosimilar products.
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Limited, has announced plans to expand its oncology portfolio with the introduction of three new biosimilar candidates. The new additions include biosimilar versions of Trastuzumab/Hyaluronidase, Nivolumab, and...
Cipla names Achin Gupta as new Managing Director and Global Chief Executive Officer, set to take office on April 1, 2026.
Cipla Limited, a leading pharmaceutical company, has announced the appointment of Achin Gupta as its new Managing Director and Global Chief Executive Officer (MD & GCEO), effective April 1, 2026. Gupta will succeed Umang Vohra, who has led the company since 2016. This...
Cipla Health ventures into sexual wellness sector with introduction of Unfold brand
Cipla Health, a leading consumer healthcare company in India, has launched a new brand called Unfold, which marks its entry into the sexual wellness category. Unfold aims to promote openness, trust, and choice in intimate wellbeing, and its visual identity was...
Cipla Health and MullenLowe’s dCell launch new brand focused on sexual wellness
Cipla Health, a leading healthcare company, has launched a new brand called Unfold, marking its entry into the sexual wellness segment. The brand's design and visual identity were developed by dCell, a design agency, to redefine how intimacy is represented in India's...
Cipla Enters India’s Weight-Loss Segment with ‘Yurpeak’, a Repurposed Version of Mounjaro
India's weight-loss market has welcomed a new player with the launch of 'Yurpeak' by Cipla, a popular pharmaceutical company. Yurpeak is the brand name given to the medication Mounjaro, which has been approved by the US FDA for the treatment of type 2 diabetes....
Hypertension Alert: Beyond Genetics and Sodium Intake, Expert from Apollo Uncovers Common Daily Habits Linked to Increased Blood Pressure Risk
A senior neurologist from Apollo Hospitals, Dr. Sudhir Kumar, has highlighted the importance of everyday habits in contributing to high blood pressure. While high-sodium diets and family history are well-known risk factors, Dr. Kumar emphasizes that routine behaviors,...
Indraprastha Apollo: Ambitious Expansion Plans Unveiled, Significant Growth on the Horizon?
Indraprastha Medical, also known as Indraprastha Apollo, is a multi-specialty hospital that has experienced stagnant growth in recent years. Unlike Healthcare Global Enterprises (HCG), which focuses on chronic specialty care, Indraprastha Apollo has a broader range of...
Apollo doctor sounds alarm on India’s unseen health crisis
The Alarming Rise of Childhood Obesity in India: A Growing Public Health Concern Childhood obesity has become a significant public health challenge in India, particularly in urban areas. According to Dr. Sudhir Kumar, a neurologist at Apollo Hospitals in Hyderabad,...
Even teetotalers in tech industry prone to irreversible nerve damage, reveals Apollo neurologist, who sheds light on causes and cures.
India's thriving tech industry is home to a young and health-conscious workforce, with many professionals prioritizing their well-being by avoiding smoking, limiting alcohol consumption, and undergoing regular health check-ups. However, a growing number of young IT...
Apollo Hospitals Bolsters Organ Transplant Capabilities with Specialized Heart and Lung Transplant Unit
Apollo Hospitals has launched a dedicated Heart & Lung Transplantation and Mechanical Circulatory Support (MCS) Unit at its Seshadripuram facility in Bengaluru, Karnataka. This marks a significant milestone in the state's transplant landscape, enhancing access to...
Mysterious Stomach Pain in 13-Year-Old Solved by Apollo Doctor After CT Scan and Blood Work Yielded No Answers |
A 13-year-old boy from Maharashtra suffered from recurring episodes of severe abdominal pain and vomiting for over three years, despite numerous doctor visits and normal test results. His symptoms, which occurred every 6-8 weeks, included throbbing headaches, severe...
Hospitals pioneer a greener future in healthcare, driving the shift towards eco-friendly medical practices.
The healthcare sector is facing a paradox in its approach to protecting life. While its primary principle is "primum non nocere" or "first, do no harm," the sector itself is contributing to the climate crisis, which is having a devastating impact on human health. The...
Navi Mumbai airport has collaborated with Apollo Hospitals to establish a 24-hour on-site medical facility equipped with ICU ambulances.
Navi Mumbai International Airport (NMIA) has partnered with Apollo Hospitals to establish a 24x7 on-site medical centre at the airport. The medical centre will provide comprehensive medical care to passengers, staff, and visitors at the airport. The partnership aims...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.